UK-based vaccine developer AstraZeneca withdrew its application for Phase 3 clinical trials in the country, said the Food and Drug Administration (FDA) last week, as the manufacturer claimed that they had sufficient data for their vaccine.
FDA director general Eric Domingo however clarified that Phase 3 trials were not a prerequisite for a vaccine to be registered in the Philippines.
So far, the country has already secured an initial 2.6 million doses of AstraZeneca’s vaccine for some 1.5 million individuals in a deal inked by the government and private firms.
Late last month, private companies signed an agreement which indicated that they will pay for the antidote and donate half of the doses to the government, and the other half for private sector employees.
Vaccine czar Carlito Galvez also said that the FDA would set aside 20 million more doses priced at around $5 each.
Currently, four more companies are left applying to Phase 3 trials: Sinovac (China), Gamaleya Research Institute (Russia), Clover Biopharmaceuticals and Johnson & Johnson (Janssen Pharmaceuticals).
The World Health Organization’s Solidarity Trial is also set to begin next month. This international trial involves participants from different countries and aims to assess the effectiveness of certain drugs or treatments for the disease.
Photo: Metro US